Key result
Catheter-based renal denervation significantly decreased glycated hemoglobin from 7.9% to 6.85% (p<0.001) at 6 months in patients with type 2 diabetes and uncontrolled hypertension.
Why the study?
The study was conducted to evaluate the effect of catheter-based sympathetic renal denervation by radiofrequency ablation on glucose metabolism in patients with type 2 diabetes and uncontrolled hypertension.
Does catheter-based renal denervation improve glucose metabolism in patients with type 2 diabetes and uncontrolled hypertension?
RCT (n=60)
1:1
Does catheter-based renal denervation improve glucose metabolism in patients with type 2 diabetes and uncontrolled hypertension?
p-value: p=<0.001
Catheter-based renal denervation improves carbohydrate metabolism and lipid profiles in patients with type 2 diabetes and uncontrolled hypertension, suggesting pleiotropic metabolic benefits beyond blood pressure reduction.
Supports safety of RDN in T2DM with hypertension; leaves open effects on glucose metabolism.
Aim. To study the effect of catheter-based sympathetic renal denervation (RDN) by radiofrequency ablation on glucose metabolism in patients with type 2 diabetes and uncontrolled hypertension. Material and methods. Sixty patients were randomly assigned in a 1:1 ratio to the RDN group and the control group. Radiofrequency ablation was performed through the femoral access using a Symplicity Spyral™ renal denervation system (Medtronic, USA). Results. The technical success was 100%. There were no any complications. During the follow-up period, patients in the RDN group showed a significant decrease in the average level of glycated hemoglobin — from 7,9 (6,83-8,35) to 6,85 (6,12-7,10)% (p<0,001) and basal glycemia — from 9,5 (7,17-10,28) to 7,55 (6,43-8,95) mmol/l (p<0,001) with no significant changes in the control group. Changes in glucose levels and the degree of insulin resistance correlated with a decrease in office systolic blood pressure (r=0,36, p=0,005). After 6-month follow-up period in the RDN group, along with a significant decrease in the HOMA-IR by 1,92 (p<0,001), the average high-density lipoprotein cholesterol level also significantly increased by 0,17 mmol/l (p<0,001), and mean triglyceride level decreased by -0,55 mmol/l (p<0,001). Conclusion. The study results confirm the hypothesis of pleiotropic effects of RDN in patients with comorbid pathology associated with central sympathetic nervous system hyperactivity (diabetes, hypertension, dyslipidemia).
No takes yet. Share an insight, caveat, or question.
Feshchenko et al. (2023) conducted an RCT in Type 2 diabetes and uncontrolled hypertension (n=60). Catheter-based sympathetic renal denervation vs. Control group was evaluated on Average level of glycated hemoglobin (p=<0.001). Catheter-based renal denervation significantly decreased glycated hemoglobin from 7.9% to 6.85% (p<0.001) at 6 months in patients with type 2 diabetes and uncontrolled hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: